Resource centre

The use of electrospraying as a means of drug loading into mesoporous silica particles for enhanced dissolution, presented at the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical (PBP) Technology 2022

Understanding the Absorption, Metabolism and Excretion of Masitinib in Healthy Male Subjects.

Safety, tolerability, and pharmacokinetics of the oligomer modulator anle138b: a first-in-human randomised, double-blind, placebo-controlled Phase 1 trial

A Decade of Human ADME at Quotient Sciences: Reviewing Key Study Design Variables and Outcomes.

A Phase I Study of the Cancer-specific Vaccine FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response

Qualification of Gastroplus® PBPK modelling software to support decision-making in clinical development.

Benznidazole pharmacokinetics in adults and children: Application of PBPK modelling.

Development of a novel oral suspension formulation of a candidate API for administration to pediatric patients.

Quotient Sciences AAPS 2022 Poster, "Kilo Scale Synthesis in Daisy Chained Flow Reactors." (2R, 6R) hydroxynorketamine is a pharmaceutical undergoing trials as an antidepressant. An atom efficient synthesis route with norketamine as an intermediate is known. A low throughput flow synthesis route to norketamine had previously been developed, 2 however a manufacturing scale method was required. The objective of this study is to conduct the entire synthesis of norketamine from 2 chlorophenylcyclopentyl ketone in daisy chained reactors, built mainly from readily available parts at a throughput of > 1 kg/day.

Quotient Sciences AAPS 2022 Poster, "Formulation and Taste Assessments in First in Human Studies" is available to download here.

"A Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers." The poster was presented at the Pharmacology 2022 conference and was co-authored with our customer, Galmed Pharmaceuticals

A Phase 1, Randomized, Double-Blind, PlaceboControlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers